Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
The New York Proton Center
Eli Lilly and Company
Exscientia AI Limited
Alliance for Clinical Trials in Oncology
Conjupro Biotherapeutics, Inc.
Zumutor Biologics Inc.
AstraZeneca
PMV Pharmaceuticals, Inc
UMC Utrecht
ViroMissile, Inc.
Duke University
Washington University School of Medicine
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
IDEAYA Biosciences
Institut du Cancer de Montpellier - Val d'Aurelle
Hospices Civils de Lyon
Daiichi Sankyo
University of Nebraska
Oscotec Inc.
Kidney Cancer Research Bureau
Adela, Inc
Natera, Inc.
Second Life Therapeutics
University of Michigan
Innate Pharma
Tanabe Pharma America, Inc.
RenJi Hospital
XEOS Medical
Cancer Research UK
NeoTX Therapeutics Ltd.
DualityBio Inc.
University of Colorado, Denver
Massive Bio, Inc.
Maastricht University Medical Center
Maastricht Radiation Oncology
Washington University School of Medicine
3B Pharmaceuticals GmbH
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
The Netherlands Cancer Institute
Brigham and Women's Hospital
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.